Gold for NovoArc at the Born Global Champion Awards

This recognition marks an important milestone in our journey from Austria to the world. The award was secured following a compelling pitch by CPO Oliver Spadiut, who presented NovoArc’s vision, achievements, and international growth strategy to the jury. It reflects not only our progress as a company, but also the dedication, expertise, and commitment of the entire NovoArc team. As we continue to grow, our focus remains clear: advancing next-generation lipid technologies and enabling innovative therapeutic solutions for partners around the world. We are proud of how far we have come and excited for the path ahead.

News

MALASSA Project Launched: NovoArc Develops Lipid Nanoparticle Platform for a New Antibody Therapy Against Lassa Fever

At the kick-off meeting in Amsterdam, the partners of the MALASSA project met in person for the first time. NovoArc is part of the consortium and contributes its expertise in lipid nanoparticles.

Read more

Eurostars project NO-PNP launched: a new approach to neuropathic pain

Together with Akasi Pharma and IVRS AB, NovoArc is developing a long-acting, non-opioid treatment for neuropathic pain. NovoArc is contributing its liposomal TEL platform to the project.

Read more

Recognized Among Austria’s Top 100 Startups

We’re incredibly proud to share that our company has been selected for TREND Magazine’s 2025 ranking of Austria’s Top 100 Startups.

Read more

More Than Teammates

Sometimes the most important work happens away from our desks.

Read more

A Visit from District Mayor Zankl

We were delighted to welcome District Mayor Zankl to our facility.

Read more

Nanoparticle Formulation Symposium 2025

We were pleased to contribute to the Nanoparticle Formulation Symposium in London as an invited speaker, sharing insights into current and emerging approaches in nanoparticle development.

Read more